ArticleObesity surgery2025
Mid-term Outcomes in Primary Roux-en-Y Gastric Bypass Procedures with Short or Long Biliopancreatic Limb.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study reports mid-term results on weight loss and T2D remission in patients undergoing Roux-en-Y gastric bypass (RYGB) with short versus long biliopancreatic limb (BPL).
methodsAll patients with obesity undergoing RYGB procedures with long BPL (150 cm) versus short BPL (60 cm) between 2016 and 2021 at a tertiary reference center for bariatric surgery were compared using propensity score matching to assess for T2D remission, HbA1c evolution, weight loss and nutritional deficiencies.
resultsA total of 165 patients were included, 69 patients (71% female, mean age 43.9 ± 14 years, mean baseline BMI 42.4 ± 4.3 kg/m
conclusionImplementation of a long-BPL RYGB is safe and shows an accelerated weight loss and improved HbA1c reduction with low overall morbidity after 2 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.